Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 72 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Chemotherapy with Temodar. Clear all
Completed Phase 1 Interventional

Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma

NCT01576692
View directory record Official record
Conditions
Neuroblastoma
Interventions
Humanized anti-GD2 antibody, Chemotherapy, Cytokines, Natural killer cells, CliniMACS
Biological · Drug · Other + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 30, 2026, 2:33 AM EDT
Active, not recruiting Phase 2 Interventional

DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab

NCT03688178
View directory record Official record
Conditions
Glioblastoma
Interventions
Human CMV pp65-LAMP mRNA-pulsed autologous DCs, Temozolomide, Varlilumab, Td, Unpulsed DCs
Biological · Drug
Lead sponsor
Annick Desjardins, MD
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Phase 2 Interventional Results available

Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma

NCT00098865
View directory record Official record
Conditions
Central Nervous System Tumor, Pediatric, Neuroblastoma
Interventions
temozolomide, thalidomide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Phase 1 Interventional

Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer

NCT02903069
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma
Interventions
MRZ, TMZ, RT, Optune
Drug · Radiation · Device
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
La Jolla, California • Orange, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

NCT03426891
View directory record Official record
Conditions
Glioblastoma, Brain Tumor, GBM
Interventions
Pembrolizumab, Vorinostat, Temozolomide, Radiotherapy
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 30, 2026, 2:33 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

NCT03581292
View directory record Official record
Conditions
Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma
Interventions
Radiation Therapy, Temozolomide, Veliparib
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 25 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
145
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 30, 2026, 2:33 AM EDT
Recruiting Phase 3 Interventional

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NCT06172296
View directory record Official record
Conditions
Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dinutuximab, Doxorubicin, Echocardiography Test, Etoposide, FDG-Positron Emission Tomography and Computed Tomography Scan, Hematopoietic Cell Transplantation, Irinotecan, Isotretinoin, Leukapheresis, Magnetic Resonance Imaging, Melphalan, Multigated Acquisition Scan, Radiation Therapy, Radionuclide Imaging, Survey Administration, Temozolomide, Thiotepa, Topotecan, Tumor Resection, Vincristine
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
157
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 127 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 30, 2026, 2:33 AM EDT
Terminated Phase 1 Interventional

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

NCT01409174
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Temozolomide, Cisplatin, Interferon Alfa-2b, Interleukin-2
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Phase 1 Interventional

Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies

NCT02392793
View directory record Official record
Conditions
Childhood Solid Tumors
Interventions
Talazoparib, Irinotecan, Temozolomide, Filgrastim, Peg-filgrastim
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Months to 25 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Sep 30, 2026, 2:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

NCT00669669
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Filgrastim, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, O6-Benzylguanine, Plerixafor, Proton Beam Radiation Therapy, Temozolomide
Radiation · Procedure · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Sep 30, 2026, 2:33 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy

NCT02446704
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Olaparib, Temozolomide
Drug
Lead sponsor
Zofia Piotrowska
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Phase 2 Interventional Results available

DC Migration Study for Newly-Diagnosed GBM

NCT02366728
View directory record Official record
Conditions
Glioblastoma, Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme
Interventions
Unpulsed DCs, Td, Human CMV pp65-LAMP mRNA-pulsed autologous DCs, 111In-labeled DCs, Temozolomide, Saline, Basiliximab
Biological · Drug
Lead sponsor
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Other
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 30, 2026, 2:33 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme

NCT02344355
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Temozolomide, radiation therapy, Ascorbic Acid
Drug · Radiation
Lead sponsor
Bryan Allen
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Sep 30, 2026, 2:33 AM EDT
Terminated Phase 2 Interventional Results available

Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma

NCT00568451
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
carboplatin, paclitaxel, temozolomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Early Phase 1 Interventional

A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas

NCT00890786
View directory record Official record
Conditions
Newly Diagnosed High-Grade Gliomas, Diffuse Intrinsic Pontine Glioma
Interventions
Temozolomide, Bevacizumab, Irinotecan
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 30 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

NCT03914742
View directory record Official record
Conditions
IDH1 Mutation, IDH2 Mutation, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma
Interventions
PARP Inhibitor BGB-290, Temozolomide, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Phase 2 Interventional Results available

Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma

NCT03746080
View directory record Official record
Conditions
Glioblastoma, Glioblastoma With Primitive Neuronal Component, Gliosarcoma, Malignant Glioma, Oligodendroglial Component Present
Interventions
Plerixafor, Temozolomide, Whole-Brain Radiotherapy (WBRT), Radiation Therapy
Drug · Radiation
Lead sponsor
Lawrence D Recht
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Sep 30, 2026, 2:33 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

NCT05432791
View directory record Official record
Conditions
Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Pazopanib, Temozolomide, Trabectedin, Transthoracic Echocardiography Test
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
144
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 30, 2026, 2:33 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

NCT03607643
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
Interventions
Cannabidiol, Bortezomib, Leucovorin, 5-FU, Oxaliplatin, Bevacizumab, Irinotecan, Gemcitabine, Temozolomide
Drug
Lead sponsor
Leaf Vertical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Phase 1 Interventional

A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma

NCT00792012
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Hypofractionated Intensity-Modulated Radiation Therapy, Temozolomide
Radiation · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 30, 2026, 2:33 AM EDT
Recruiting Phase 1 Interventional

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

NCT06475235
View directory record Official record
Conditions
Lymphoma, Primary Central Nervous System Lymphoma
Interventions
Pembrolizumab, Methotrexate, Temozolomide, Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Phase 2 Interventional Results available

Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors

NCT00302159
View directory record Official record
Conditions
High Grade Gliomas, Brain Tumors
Interventions
adjuvant therapy, Temozolomide, Valproic Acid, Radiation therapy
Procedure · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
3
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Sep 30, 2026, 2:33 AM EDT
Completed Phase 1 Interventional

Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma

NCT01858168
View directory record Official record
Conditions
Ewing Sarcoma, Rhabdomyosarcoma
Interventions
Olaparib, Temozolomide, Irinotecan
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
5
States / cities
Boston, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Sep 30, 2026, 2:33 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme

NCT01822275
View directory record Official record
Conditions
Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV)
Interventions
Chemotherapy with Temodar., Radiation therapy
Drug · Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Sep 30, 2026, 2:33 AM EDT